Modified tectonic corneoscleral graft technique for treating devastating corneoscleral infections.
Corneoscleral graft
Corneoscleral infection
Keratoplasty
Treatment
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
28
06
2024
accepted:
03
09
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
This study aims to evaluate the clinical outcomes and efficacy of a modified tectonic corneoscleral graft (TCG) in patients suffering from devastating corneoscleral infections. Thirty-eight eyes from 38 patients who underwent the modified TCG were included in this study. The outcomes measured were recurrence rates, best-corrected visual acuity (BCVA), ocular surface stability, postoperative complications, and graft survival. Among the 38 patients, 23 had fungal infections, 9 had bacterial infections and 6 had Pythium insidiosum infections. At the final follow-up, with an average duration of 25.1 ± 8.6 months, the rate of monocular blindness decreased from 100 to 58%. Significant improvements in LogMAR BCVA were observed from preoperative to postoperative measurements (P < 0.001). Thirty-two eyes (84.2%) maintained a stable ocular surface. The survival rate of ocular surface stability was 84.2%±5.9% at one year and 57.7%±9.7% at three years post-surgery. Twenty eyes (52.6%) retained a clear graft, with a survival rate for graft clarity was 81.6%±6.3% at one year and 36.0%±10.8% at three years post-surgery. The incidence of immune rejection was 36.8%. Corneal epithelial defects were observed in ten patients, and choroidal detachment occurred in four patients. No cases of elevated intraocular pressure were detected. The modified TCG is effective in eradicating infections, preserving the eyeball, and maintaining useful vision in cases of devastating corneoscleral infections. Regular use of tacrolimus, timely administration of glucocorticoids, and good patient compliance can help mitigate postoperative challenges.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to evaluate the clinical outcomes and efficacy of a modified tectonic corneoscleral graft (TCG) in patients suffering from devastating corneoscleral infections.
METHODS
METHODS
Thirty-eight eyes from 38 patients who underwent the modified TCG were included in this study. The outcomes measured were recurrence rates, best-corrected visual acuity (BCVA), ocular surface stability, postoperative complications, and graft survival.
RESULTS
RESULTS
Among the 38 patients, 23 had fungal infections, 9 had bacterial infections and 6 had Pythium insidiosum infections. At the final follow-up, with an average duration of 25.1 ± 8.6 months, the rate of monocular blindness decreased from 100 to 58%. Significant improvements in LogMAR BCVA were observed from preoperative to postoperative measurements (P < 0.001). Thirty-two eyes (84.2%) maintained a stable ocular surface. The survival rate of ocular surface stability was 84.2%±5.9% at one year and 57.7%±9.7% at three years post-surgery. Twenty eyes (52.6%) retained a clear graft, with a survival rate for graft clarity was 81.6%±6.3% at one year and 36.0%±10.8% at three years post-surgery. The incidence of immune rejection was 36.8%. Corneal epithelial defects were observed in ten patients, and choroidal detachment occurred in four patients. No cases of elevated intraocular pressure were detected.
CONCLUSIONS
CONCLUSIONS
The modified TCG is effective in eradicating infections, preserving the eyeball, and maintaining useful vision in cases of devastating corneoscleral infections. Regular use of tacrolimus, timely administration of glucocorticoids, and good patient compliance can help mitigate postoperative challenges.
Identifiants
pubmed: 39261792
doi: 10.1186/s12886-024-03669-2
pii: 10.1186/s12886-024-03669-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
402Subventions
Organisme : National Natural Science Foundation of China
ID : 82070923
Organisme : Taishan Scholar Program
ID : 201812150
Organisme : Academic Promotion Program and Innovation Project of Shandong First Medical University
ID : 2019RC009
Informations de copyright
© 2024. The Author(s).
Références
Khor WB, Prajna VN, Garg P, et al. The Asia Cornea Society Infectious Keratitis Study: a prospective Multicenter Study of Infectious Keratitis in Asia. Am J Ophthalmol. 2018;195:161–70.
doi: 10.1016/j.ajo.2018.07.040
pubmed: 30098351
Pan X, Jiang T, Zhu H, et al. Corneal infection in Shandong Peninsula of China: a 10-year retrospective study on 578 cases. Int J Ophthalmol. 2016;9(1):53–7.
pubmed: 26949610
pmcid: 4768492
Song X, Xie L, Tan X, et al. A multi-center, cross-sectional study on the burden of infectious keratitis in China. PLoS ONE. 2014;9(12):e113843.
doi: 10.1371/journal.pone.0113843
pubmed: 25438169
pmcid: 4250054
Cao J, Yang Y, Yang W, et al. Prevalence of infectious keratitis in Central China. BMC Ophthalmol. 2014;14:43.
doi: 10.1186/1471-2415-14-43
pubmed: 24690368
pmcid: 3976152
Reynolds M, Alfonso E. Treatment of infectious scleritis and keratoscleritis. Am J Ophthalmol. 1991;112(5):543–7.
doi: 10.1016/S0002-9394(14)76856-4
pubmed: 1951592
Czako C, Sandor G, Popper-Sachetti A, et al. Ocular manifestations and management of Fusarium and Sarocladium infections. Orv Hetil. 2019;160(1):2–11.
pubmed: 30599781
Zhao B, Xu X, Li B, et al. Eye enucleations in Beijing Tongren Hospital in the last 50 years. Br J Ophthalmol. 2013;97(1):107–8.
doi: 10.1136/bjophthalmol-2012-301630
pubmed: 23137663
Alfaro Rangel R, Szentmary N, Lepper S, et al. Large-diameter penetrating keratoplasties are mostly due to very severe infectious keratitis and cannot always prevent secondary Enucleation. Klin Monbl Augenheilkd. 2022;239(11):1361–8.
doi: 10.1055/a-1396-4787
pubmed: 33853185
Thatte S, Dube AB, Dubey T, Krishnan M. Outcome of Sclerokeratoplasty in Devastating Sclerocorneal infections. J Curr Ophthalmol. 2020;32(1):38–45.
doi: 10.4103/JOCO.JOCO_24_20
pubmed: 32510012
pmcid: 7265277
Zhong J, Wang B, Li S, et al. Full-thickness conjunctival flap covering surgery combined with amniotic membrane transplantation for severe fungal keratitis. Exp Ther Med. 2018;15(3):2711–8.
pubmed: 29456673
pmcid: 5795562
Cowden JW, Copeland RA Jr., Schneider MS. Large diameter therapeutic penetrating keratoplasties. Refract Corneal Surg. 1989;5(4):244–8.
doi: 10.3928/1081-597X-19890701-09
pubmed: 2488813
Hirst L, Lee G. Corneoscleral transplantation for end stage corneal disease. Br J Ophthalmol. 1998;82(11):1276–9.
doi: 10.1136/bjo.82.11.1276
pubmed: 9924332
pmcid: 1722436
Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15(4):321–7.
doi: 10.1097/00055735-200408000-00008
pubmed: 15232472
Mahmoudi S, Masoomi A, Ahmadikia K, et al. Fungal keratitis: an overview of clinical and laboratory aspects. Mycoses. 2018;61(12):916–30.
doi: 10.1111/myc.12822
pubmed: 29992633
Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113(11):1943–8.
doi: 10.1016/j.ophtha.2006.05.035
pubmed: 16935335
Gaastra W, Lipman LJ, De Cock AW, et al. Pythium insidiosum: an overview. Vet Microbiol. 2010;146(1–2):1–16.
doi: 10.1016/j.vetmic.2010.07.019
pubmed: 20800978
Hasika R, Lalitha P, Radhakrishnan N, et al. Pythium keratitis in South India: incidence, clinical profile, management, and treatment recommendation. Indian J Ophthalmol. 2019;67(1):42–7.
doi: 10.4103/ijo.IJO_445_18
pubmed: 30574890
pmcid: 6324135
Jain R, Bhutia K, Mohan N, et al. Outcome of therapeutic keratoplasty in hopeless microbial keratitis cases otherwise advised Evisceration. Volume 37. Cornea; 2018. pp. 151–5. 2.
Kumar S, Panda A. Fibrin glue aided sutureless sclerokeratoplasty with maintenance of chamber angle. Cornea. 2011;30(5):588–90.
doi: 10.1097/ICO.0b013e3182000fbb
pubmed: 21598431
Schmitz K, Behrens-Baumann W. Penetrating re-keratoplasty a chaud using healon 5 for stabilizing the anterior chamber. Ophthalmologe. 2000;97(8):566–70.
doi: 10.1007/s003470070067
pubmed: 10994335
Skeens HM, Holland EJ. Large-diameter penetrating keratoplasty: indications and outcomes. Cornea. 2010;29(3):296–301.
doi: 10.1097/ICO.0b013e3181b6489e
pubmed: 20118782
Chen X, Li X, Zhang X, et al. Comparison of complications and visual outcomes between big-bubble deep anterior lamellar keratoplasty and penetrating keratoplasty for fungal keratitis. Clin Exp Ophthalmol. 2021;49(6):550–9.
doi: 10.1111/ceo.13951
pubmed: 34032343
Anshu A, Parthasarathy A, Mehta JS, et al. Outcomes of therapeutic deep lamellar keratoplasty and penetrating keratoplasty for advanced infectious keratitis: a comparative study. Ophthalmology. 2009;116(4):615–23.
doi: 10.1016/j.ophtha.2008.12.043
pubmed: 19243833
Ayalew M, Tilahun Y, Holsclaw D, et al. Penetrating Keratoplasty at a Tertiary Referral Center in Ethiopia: indications and outcomes. Cornea. 2017;36(665–8):6.
Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transpl Proc. 1998;30(4):1573–9.
doi: 10.1016/S0041-1345(98)00361-3
Abudou M, Wu T, Evans JR, Chen X. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. Cochrane Database Syst Rev. 2015;2015(8):CD007603.
pubmed: 26313245
pmcid: 9233756
Armitage WJ, Goodchild C, Griffin MD, et al. High-risk corneal transplantation: recent developments and future possibilities. Transplantation. 2019;103(12):2468–78.
doi: 10.1097/TP.0000000000002938
pubmed: 31765363
pmcid: 6867666
Zhu BB, Zhou J, Zheng J, et al. Corneal graft melting: a systematic review. Int J Ophthalmol. 2020;13(3):493–502.
doi: 10.18240/ijo.2020.03.19
pubmed: 32309189
pmcid: 7154193
Stryjewski TP, Chodosh J, Kim IK, et al. Severe corneal ulcer with progression to endophthalmitis and high-grade bacteremia. Am J Ophthalmol Case Rep. 2017;6:30–2.
doi: 10.1016/j.ajoc.2017.02.001
pubmed: 29260050
pmcid: 5722188
Mundra J, Dhakal R, Mohamed A, et al. Outcomes of therapeutic penetrating keratoplasty in 198 eyes with fungal keratitis. Indian J Ophthalmol. 2019;67(10):1599–605.
doi: 10.4103/ijo.IJO_1952_18
pubmed: 31546488
pmcid: 6786177
Wang T, Li S, Gao H, et al. Therapeutic dilemma in fungal keratitis: administration of steroids for immune rejection early after keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1585–9.
doi: 10.1007/s00417-016-3412-0
pubmed: 27342585
Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol. 2008;28(3):223–32.
doi: 10.1007/s10792-007-9100-7
pubmed: 17634865
Xiang DM, Wang YX, Jia YN, et al. The observation of tacrolimus eye drops preventing the early immunological rejection after penetrating keratoplasty for fungal keratitis. Zhonghua Yan Ke Za Zhi. 2017;53(4):305–10.
pubmed: 28412805
Li X, Zhang YN, Yin MY, Pan ZQ. The effectiveness and safety of topical 0.1% tacrolimus after high-risk penetrating keratoplasty. Zhonghua Yan Ke Za Zhi. 2019;55(6):419–27.
pubmed: 31189271
Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136–42.
doi: 10.1016/0167-5699(92)90111-J
pubmed: 1374612
Young AL, Rao SK, Cheng LL, et al. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye (Lond). 2002;16(3):304–8.
doi: 10.1038/sj.eye.6700144
pubmed: 12032722
Panda A, Vanathi M, Kumar A, et al. Corneal graft rejection. Surv Ophthalmol. 2007;52(4):375–96.
doi: 10.1016/j.survophthal.2007.04.008
pubmed: 17574064
Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83(12):1348–52.
doi: 10.1136/bjo.83.12.1348
pubmed: 10574812
pmcid: 1722899